Susan E. Bates

51.5k total citations · 8 hit papers
453 papers, 38.5k citations indexed

About

Susan E. Bates is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Susan E. Bates has authored 453 papers receiving a total of 38.5k indexed citations (citations by other indexed papers that have themselves been cited), including 293 papers in Oncology, 205 papers in Molecular Biology and 62 papers in Cancer Research. Recurrent topics in Susan E. Bates's work include Drug Transport and Resistance Mechanisms (153 papers), Histone Deacetylase Inhibitors Research (70 papers) and Cancer therapeutics and mechanisms (54 papers). Susan E. Bates is often cited by papers focused on Drug Transport and Resistance Mechanisms (153 papers), Histone Deacetylase Inhibitors Research (70 papers) and Cancer therapeutics and mechanisms (54 papers). Susan E. Bates collaborates with scholars based in United States, United Kingdom and Israel. Susan E. Bates's co-authors include Tito Fojo, Michael M. Gottesman, Robert W. Robey, Michael Dean, Antonio Tito Fojo, Thomas Litman, Richard Piekarz, Orsolya Polgár, Wilfred D. Stein and Zhirong Zhan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Susan E. Bates

434 papers receiving 37.8k citations

Hit Papers

Multidrug resistance in c... 1999 2026 2008 2017 2002 2005 2018 1999 2003 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multidrug resistance in cancer: role of ATP–dependent transporters
    2002 4.5k citations Tito Fojo, Susan E. Bates et al. profile →
  2. Tumour stem cells and drug resistance
    2005 3.0k citations Tito Fojo, Susan E. Bates et al. profile →
  3. Revisiting the role of ABC transporters in multidrug-resistant cancer
    2018 1.4k citations Robert W. Robey, Susan E. Bates et al. profile →
  4. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
    1999 674 citations Thomas Litman, Zhirong Zhan et al. profile →
  5. The Role of ABC Transporters in Clinical Practice
    2003 648 citations Tito Fojo, Susan E. Bates et al. profile →
  6. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
    2001 574 citations Thomas Litman, Wilfred D. Stein et al. profile →
  7. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
    2009 561 citations Richard Piekarz, Robin Frye et al. profile →
  8. Epigenetic Therapies for Cancer
    2020 320 citations Susan E. Bates profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Susan E. Bates 22.9k 20.1k 4.4k 4.4k 3.5k 453 38.5k
Michael M. Gottesman 32.9k 1.4× 27.8k 1.4× 4.3k 1.0× 7.8k 1.8× 4.9k 1.4× 408 53.6k
Godefridus J. Peters 16.5k 0.7× 18.0k 0.9× 5.6k 1.3× 1.3k 0.3× 2.8k 0.8× 854 35.0k
Herbert M. Pinedo 15.8k 0.7× 12.1k 0.6× 3.5k 0.8× 1.4k 0.3× 3.0k 0.9× 571 29.8k
Elisabeth G.E. de Vries 24.1k 1.1× 14.3k 0.7× 6.4k 1.4× 2.4k 0.5× 5.2k 1.5× 1.0k 47.8k
Takashi Tsuruo 12.4k 0.5× 16.6k 0.8× 2.8k 0.6× 1.9k 0.4× 1.9k 0.5× 446 27.7k
Hiroshi Suzuki 9.2k 0.4× 10.7k 0.5× 3.6k 0.8× 3.3k 0.8× 3.4k 1.0× 533 25.8k
Tito Fojo 13.2k 0.6× 11.7k 0.6× 4.7k 1.1× 1.4k 0.3× 3.1k 0.9× 265 24.3k
Howard L. McLeod 10.1k 0.4× 9.6k 0.5× 2.9k 0.7× 2.6k 0.6× 1.9k 0.5× 481 26.6k
Mark C. Willingham 9.4k 0.4× 17.6k 0.9× 2.2k 0.5× 1.9k 0.4× 3.2k 0.9× 425 33.5k
Suresh V. Ambudkar 14.4k 0.6× 11.1k 0.6× 1.4k 0.3× 3.7k 0.8× 2.1k 0.6× 315 23.8k

Countries citing papers authored by Susan E. Bates

Since Specialization
Citations

This map shows the geographic impact of Susan E. Bates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan E. Bates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan E. Bates more than expected).

Fields of papers citing papers by Susan E. Bates

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan E. Bates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan E. Bates. The network helps show where Susan E. Bates may publish in the future.

Co-authorship network of co-authors of Susan E. Bates

This figure shows the co-authorship network connecting the top 25 collaborators of Susan E. Bates. A scholar is included among the top collaborators of Susan E. Bates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan E. Bates. Susan E. Bates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Sai-Wen, Anish Thomas, Junko Murai, et al.. (2018). Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research. 24(8). 1944–1953. 65 indexed citations
2.
Lee, Hee-Sheung, Nathan Lee, Natalay Kouprina, et al.. (2016). Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Research. 76(4). 902–911. 57 indexed citations
3.
Jain, Salvia, Kelly Zullo, Luigi Scotto, et al.. (2015). Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research. 21(9). 2096–2106. 49 indexed citations
4.
Appleman, Leonard J., Sanjeeve Balasubramaniam, Robert A. Parise, et al.. (2014). A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clinical Cancer Research. 21(4). 721–729. 5 indexed citations
5.
Amiri‐Kordestani, Laleh, Victoria Luchenko, Cody J. Peer, et al.. (2013). Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. Clinical Cancer Research. 19(16). 4499–4507. 57 indexed citations
6.
Noonan, Anne M., David J. Liewehr, Tristan M. Sissung, et al.. (2013). Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel. Clinical Cancer Research. 19(11). 3095–3104. 39 indexed citations
7.
Basseville, Agnès, Akina Tamaki, Caterina Ieranò, et al.. (2012). Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter. Cancer Research. 72(14). 3642–3651. 32 indexed citations
8.
Wang, Chunxi, Zhihui Liu, Zhijie Li, et al.. (2011). EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1 , CLU , RUNX3 , and NGFR. Cancer Research. 72(1). 315–324. 140 indexed citations
9.
Shi, Zhi, Amit K. Tiwari, Suneet Shukla, et al.. (2011). Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research. 71(8). 3029–3041. 152 indexed citations
10.
To, Kenneth K.W., et al.. (2011). Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway. Molecular Cancer Research. 9(4). 516–527. 43 indexed citations
11.
Stein, Wilfred D., James L. Gulley, Jeff Schlom, et al.. (2010). Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clinical Cancer Research. 17(4). 907–917. 201 indexed citations
12.
Sissung, Tristan M., Erin R. Gardner, Richard Piekarz, et al.. (2010). Impact of ABCB1 Allelic Variants on QTc Interval Prolongation. Clinical Cancer Research. 17(4). 937–946. 24 indexed citations
13.
Kelly, Ronan J., Deborah Draper, Clara C. Chen, et al.. (2010). A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research. 17(3). 569–580. 151 indexed citations
14.
To, Kenneth K.W., Robert W. Robey, Turid Knutsen, et al.. (2009). Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Molecular Cancer Therapeutics. 8(10). 2959–2968. 86 indexed citations
15.
Abraham, Jame, Maureen Edgerly, Richard H. Wilson, et al.. (2009). A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research. 15(10). 3574–3582. 93 indexed citations
16.
To, Kenneth K.W., Zhirong Zhan, Thomas Litman, & Susan E. Bates. (2008). Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line. Molecular and Cellular Biology. 28(17). 5147–5161. 137 indexed citations
17.
To, Kenneth K.W., Orsolya Polgár, Lyn M. Huff, Kuniaki Morisaki, & Susan E. Bates. (2008). Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells. Molecular Cancer Research. 6(1). 151–164. 102 indexed citations
18.
Zhuang, Sen Hong, Robert W. Robey, Dan L. Sackett, et al.. (2007). Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone. Clinical Cancer Research. 13(24). 7480–7486. 23 indexed citations
19.
Stein, Wilfred D., Thomas Litman, Tito Fojo, & Susan E. Bates. (2004). A Serial Analysis of Gene Expression (SAGE) Database Analysis of Chemosensitivity. Cancer Research. 64(8). 2805–2816. 101 indexed citations
20.
Bates, Susan E., Clara Chen, Robert W. Robey, et al.. (2002). Reversal of Multidrug Resistance: Lessons from Clinical Oncology. Novartis Foundation symposium. 243. 83–102. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael M. Gottesman Breakdown of academic impact, for papers by Godefridus J. Peters Breakdown of academic impact, for papers by Herbert M. Pinedo Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by Takashi Tsuruo Breakdown of academic impact, for papers by Hiroshi Suzuki Breakdown of academic impact, for papers by Tito Fojo Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Mark C. Willingham Breakdown of academic impact, for papers by Suresh V. Ambudkar
Rankless by CCL
2026